United States Patent 6,642,245: Scope, Claims, Expiration, and Emtricitabine Patent Landscape

U.S. Patent 6,642,245 is a method-of-treatment patent covering the use of both enantiomers of 5-fluoro-1,3-oxathiolane cytidine analogs, their mono-, di-, and triphosphate forms, and pharmaceutical formulations for treating HIV infection. The L-enantiomer is emtricitabine, also known as FTC or (-)-β-L-2′,3′-dideoxy-5-fluoro-3′-thiacytidine.

The patent issued on November 4, 2003, and its principal commercial relevance was tied to emtricitabine products marketed by Gilead Sciences, including Emtriva, Truvada, Atripla, Complera, Stribild, and later combination products. The patent’s term expired in 2021, subject to the official patent-term calculation and any applicable adjustment. It no longer creates a current U.S. blocking right.

What does U.S. Patent 6,642,245 cover?

Patent 6,642,245 covers methods of treating HIV infection in humans by administering:

The L-enantiomer of the claimed fluorinated oxathiolane nucleoside, namely emtricitabine.
The corresponding D-enantiomer.
The mono-, di-, or triphosphate forms of either enantiomer.
Pharmaceutical compositions containing those active agents.
Oral dosage forms, including capsules and tablets.
Parenteral administration.
Isolated enantiomers or compositions at least 95% free of the opposite enantiomer.

The patent is a use patent. It does not principally claim the chemical compound as a composition of matter. That distinction limits infringement analysis to conduct involving treatment of HIV infection and administration of a covered compound or phosphate form.

Patent identification

Item	Data
U.S. patent	6,642,245
Title	Methods of treating HIV infection
Issue date	November 4, 2003
Patent type	Method of treatment
Therapeutic area	HIV infection
Principal commercial compound	Emtricitabine, FTC
Covered stereochemistry	L- and D-enantiomers
Covered forms	Free nucleoside, physiologically acceptable salts, mono-, di-, and triphosphates
Dosage forms	Oral, capsule, tablet, and parenteral
Historical commercial relevance	Emtriva and emtricitabine-containing combinations
U.S. status	Expired in 2021

The patent record should be read together with the issued claims, prosecution history, assignment records, and FDA patent listings. Patent databases can display continuation, priority, and expiration data differently from the FDA Orange Book or the USPTO patent-term database. [1,2]

How should the 22 claims be interpreted?

The claims divide into four substantive groups.

Claims 1 through 8: L-enantiomer treatment claims

Claim 1 covers treating HIV infection in humans by administering an effective amount of the L-enantiomer, or a physiologically acceptable salt, with an optional pharmaceutically acceptable carrier.

This is the core emtricitabine method claim. Claims 2 through 5 narrow the carrier or route:

Claim 2: carrier suitable for oral delivery.
Claim 3: capsule.
Claim 4: tablet.
Claim 5: parenteral administration.

Claims 6 through 8 address stereochemical purity:

At least 95% free of the corresponding D-enantiomer.
Administration as an isolated enantiomer.

Claims 6 and 7 are materially duplicative as supplied. The issued patent should control if there is a transcription difference or correction in the official record.

Claims 9 through 16: D-enantiomer treatment claims

Claim 9 covers HIV treatment using the corresponding D-enantiomer. Claims 10 through 13 parallel claims 2 through 5, while claims 14 through 16 address purity and isolation.

These claims are important for claim scope even though the D-enantiomer did not become the principal commercial HIV product. A claim can be commercially significant as a fallback or blocking claim even when the claimed alternative is not marketed.

The D-enantiomer claims also create potential prosecution-history and enablement issues. A party assessing historical enforceability would examine whether the specification enabled treatment with the D-enantiomer across the full claim scope and whether the claims survived any written-description or utility challenge.

Claims 17 through 19: L-enantiomer phosphate forms

Claim 17 covers treatment using the monophosphate, diphosphate, or triphosphate of the L-enantiomer. Claims 18 and 19 narrow the claims to stereochemical purity and isolated-enantiomer status.

The claims use the term “monphosphate” in the supplied text. That appears to be a typographical transcription of “monophosphate.” The issued patent text and certificate history are controlling.

These claims reach phosphorylated forms associated with intracellular activation of nucleoside analogs. They do not automatically cover every prodrug, salt, ester, or fixed-dose combination containing emtricitabine. A separate claim-construction analysis would be required for a chemically modified prodrug.

Claims 20 through 22: D-enantiomer phosphate forms

Claim 20 covers the corresponding mono-, di-, and triphosphates of the D-enantiomer. Claims 21 and 22 address purity and isolated-enantiomer status.

Together, claims 17 through 22 broaden the patent beyond administration of the parent nucleoside. They also create a potential distinction between:

Administration of emtricitabine itself.
Administration of a phosphate metabolite or derivative.
Intracellular phosphorylation occurring after administration.
Administration of a separately isolated phosphorylated compound.

That distinction matters because ordinary emtricitabine treatment does not necessarily mean that a physician administered the mono-, di-, or triphosphate as the pharmaceutical product.

What is the patent scope for emtricitabine products?

The practical scope is strongest against a product that satisfies all of the following elements:

It is administered to a human.
The purpose is treatment of HIV infection.
The administered active ingredient is emtricitabine or a covered enantiomeric or phosphate form.
The quantity is an effective amount.
The product uses a covered salt or formulation where relevant.

The patent does not require a particular dosage strength, dosing schedule, treatment duration, viral-load threshold, CD4 count, or combination partner. A claim directed to “an effective amount” can cover a range of clinically effective dosing regimens, subject to ordinary claim-construction and proof requirements.

The carrier limitations are dependent claims. A product does not need to be a capsule or tablet to implicate claim 1. Conversely, a capsule or tablet may implicate a narrower dependent claim if the independent claim’s other elements are met.

What is not necessarily covered?

The claims do not expressly cover:

HIV pre-exposure prophylaxis as a distinct indication unless it falls within “treating HIV infection.”
Hepatitis B treatment.
Post-exposure prophylaxis as an independent indication.
Every formulation containing emtricitabine.
Every fixed-dose combination automatically.
Every chemically modified emtricitabine prodrug.
Manufacturing emtricitabine.
A composition of matter standing alone, absent the claimed treatment context.

The distinction between treatment and prevention was commercially important. Truvada was later approved for HIV pre-exposure prophylaxis, but a prevention indication does not automatically satisfy a claim limited to treating HIV infection. The label, prescribing conduct, marketing evidence, and claim construction would determine the analysis.

When did U.S. Patent 6,642,245 expire?

The patent expired in 2021 based on its applicable U.S. patent term. Commercial patent references commonly identify an expiration date in August 2021 for this patent family. The controlling date is the USPTO patent-term record, including any terminal disclaimer, patent-term adjustment, or correction. [1]

The practical timeline was:

Event	Date or period
Patent application and prosecution	Early 2000s
Patent issued	November 4, 2003
FDA approval of Emtriva	2003
Five-year NCE exclusivity period	Approximately 2003-2008
Historical Orange Book relevance	During the marketed-product exclusivity period
Patent expiration	2021
Current blocking effect	None after expiration

Patent expiration is separate from FDA regulatory exclusivity. A patent can continue after NCE exclusivity ends, and FDA exclusivity can end before patent expiration.

What was the FDA regulatory status of emtricitabine?

The FDA approved Emtriva, containing emtricitabine, in 2003 for use with other antiretroviral agents for treatment of HIV-1 infection. Emtricitabine was approved as a nucleoside reverse transcriptase inhibitor. [3]

Key regulatory milestones included:

Product	Active ingredient or combination	Regulatory significance
Emtriva	Emtricitabine	Standalone FTC product
Truvada	Emtricitabine/tenofovir disoproxil fumarate	HIV treatment and later PrEP
Atripla	Efavirenz/emtricitabine/tenofovir DF	Fixed-dose HIV regimen
Complera	Rilpivirine/emtricitabine/tenofovir DF	Fixed-dose HIV regimen
Stribild	Elvitegravir/cobicistat/emtricitabine/tenofovir DF	Integrase inhibitor combination
Genvoya	Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide	TAF-based combination
Biktarvy	Bictegravir/emtricitabine/tenofovir alafenamide	Current major FTC-containing regimen

FDA approval of a combination product does not mean that every patent covering one component is listed against every combination. Orange Book listing depends on the approved drug, patent claim type, statutory listing rules, and the NDA holder’s submission. [4]

What was the Orange Book status of U.S. Patent 6,642,245?

U.S. Patent 6,642,245 was historically relevant to FDA-listed emtricitabine products, but Orange Book treatment must be evaluated product by product and at the relevant historical date.

The Orange Book can list:

Composition-of-matter patents.
Formulation patents.
Method-of-use patents with approved-use claims.
Certain patents associated with approved drug products.

A listed method-of-use patent generally requires a generic applicant to make a patent certification. The applicant may file:

Paragraph I: no patent information has been submitted.
Paragraph II: the patent has expired.
Paragraph III: the generic applicant will wait until expiration.
Paragraph IV: the patent is invalid, unenforceable, or will not be infringed.

After the 2021 expiration of the patent, a Paragraph II certification would be the normal historical pathway for an ANDA applicant confronting the patent, unless the patent was not listed for the specific reference product or had already been removed.

Which companies challenged or bypassed the emtricitabine patent estate?

The main competitive pressure came from generic manufacturers targeting emtricitabine-containing combination products, particularly Truvada and Atripla. Generic competition was shaped by the combined patent estates for:

Emtricitabine.
Tenofovir disoproxil fumarate.
Combination compositions.
Formulations.
Approved methods of use.

Major generic companies active in HIV antiretroviral filings have included Teva, Mylan, Cipla, Lupin, Hetero, Apotex, and other ANDA sponsors. The relevant challenge may have been directed at a Gilead combination product rather than directly at Patent 6,642,245.

A Paragraph IV filing against one patent does not invalidate the entire emtricitabine estate. Generic entry depends on whether other unexpired patents remain, whether the challenged patent is listed, whether litigation triggers a 30-month stay, and whether a settlement establishes an authorized entry date.

What patent litigation and settlements affected emtricitabine?

The commercially important disputes involved Gilead’s combination products and tenofovir-related patents as much as Patent 6,642,245 itself. Litigation risk was concentrated around:

Truvada composition and formulation patents.
Tenofovir disoproxil fumarate and fumarate salt patents.
Tenofovir alafenamide patents for newer products.
Fixed-dose combination patents.
Pediatric and dosing patents.
HIV treatment and prevention method patents.

An expired method patent does not eliminate litigation exposure from later formulation or combination patents. A generic product containing emtricitabine may avoid an expired emtricitabine treatment patent but still face a separate patent covering the combination, salt, dosage form, or manufacturing process.

How strong was the patent estate?

Strengths

Patent 6,642,245 had several structural strengths:

It covered the commercially important L-enantiomer.
It included both parent nucleoside and phosphate forms.
It included purity and isolated-enantiomer limitations.
It covered oral, capsule, tablet, and parenteral embodiments.
It required no specific dose or treatment duration.
It addressed human HIV treatment directly.

Weaknesses

Its limitations included:

It was a method patent rather than a broad composition-of-matter patent.
It depended on proving treatment of HIV infection.
It did not expressly claim every emtricitabine formulation or combination.
Prevention uses created a treatment-versus-prophylaxis distinction.
The D-enantiomer and phosphate claims had limited commercial importance.
The patent expired in 2021.
Commercial products could be defended by separate patents even if this patent were invalid or expired.

The strongest historical enforcement position would have involved a labeled HIV-treatment product containing emtricitabine in a conventional oral formulation before expiration. The weakest position would have involved an unapproved prevention use, a noncovered prodrug, or a product launched after expiration with no evidence of inducing the claimed treatment method.

Are biosimilar risks relevant to emtricitabine?

No. Emtricitabine is a small-molecule drug, not a biologic. The relevant competitive pathway is the abbreviated new drug application, not a biosimilar application under the Public Health Service Act.

The principal barriers were:

Orange Book patents.
ANDA patent certifications.
FDA exclusivity.
Manufacturing and quality requirements.
API sourcing.
Combination-product patents.
Regulatory requirements for bioequivalence and dissolution.

What manufacturing and IP barriers remain?

Patent 6,642,245 did not principally claim manufacturing methods. A manufacturer’s risk therefore turns on separate process, intermediate, crystal-form, salt, impurity, and formulation patents.

Potential manufacturing barriers include:

Stereoselective production of the L-enantiomer.
Control of D-enantiomer contamination.
Enantiomeric purity of at least 95% where relevant.
Control of cytidine analog impurities.
Phosphorylation chemistry for phosphate derivatives.
Stable oral dosage-form manufacture.
API consistency and residual-solvent control.
Supply of qualified starting materials.

The 95% purity limitations in claims 6, 7, 14, and 15 do not necessarily impose a general product-quality requirement on every emtricitabine product. They narrow particular dependent claims. A product that contains more than 5% of the opposite enantiomer could fall outside those dependent claims while still potentially implicating the independent treatment claim.

How does Patent 6,642,245 compare with the main emtricitabine patents?

Patent category	Typical scope	Commercial role
Early emtricitabine composition patents	Compound and stereochemical structure	Core molecule protection
U.S. 6,642,245	HIV treatment using L/D enantiomers and phosphate forms	Method-of-use protection
Combination patents	FTC with tenofovir or other antiretrovirals	Product-specific protection
Formulation patents	Tablets, salts, release characteristics, excipients	Product and manufacturing protection
Process patents	Synthesis, intermediates, purification	Supply-chain protection
TAF-era patents	Tenofovir alafenamide combinations	Later-generation product protection

The patent was narrower than a composition-of-matter patent but broader than a claim limited to one dosage strength or one branded formulation. Its value was highest before expiration and while emtricitabine-containing HIV treatment products had substantial sales.

What generic launch risks existed?

Before expiration, a generic entrant faced several possible outcomes:

Launch after patent expiration with no litigation settlement.
At-risk launch after a Paragraph IV challenge.
Authorized generic entry under a license or settlement.
Launch of a different formulation or combination outside the asserted claims.
Launch after removing or carving out a patented method of use.

The most important commercial risk was not Patent 6,642,245 in isolation. It was the cumulative effect of the Gilead patent portfolio across emtricitabine, tenofovir, fixed-dose combinations, formulations, and later tenofovir alafenamide products.

After expiration in 2021, Patent 6,642,245 no longer supported an injunction against a new U.S. product. Remaining exposure depended on other unexpired patents and on the product’s approved labeling.

What was the revenue exposure associated with the patent?

Patent 6,642,245 was connected to products with substantial cumulative revenue, particularly Truvada and Atripla during their peak commercial years. The patent itself cannot be assigned the full revenue of those products because:

Each product contained multiple active ingredients.
Other Gilead patents protected the combinations and components.
Market exclusivity also reflected clinical adoption, regulatory approvals, and manufacturing scale.
Product revenue continued after some underlying patents expired.

The economic exposure was therefore portfolio-level rather than attributable to a single patent. Emtricitabine remained commercially important as a component of Truvada, Atripla, Complera, Stribild, Genvoya, and Biktarvy. [3,5]

Key Takeaways

U.S. Patent 6,642,245 is a method-of-treatment patent for HIV infection.
Its central commercial subject is emtricitabine, the L-enantiomer of the claimed fluorinated oxathiolane nucleoside.
The claims cover the parent nucleoside, salts, mono-, di-, and triphosphates, both enantiomers, and selected pharmaceutical formulations.
Claims 1 and 9 are the principal parent-compound treatment claims.
Claims 17 and 20 address phosphate forms.
The patent does not broadly claim every emtricitabine composition, prodrug, combination, or manufacturing method.
The patent expired in 2021 and has no current U.S. blocking effect.
Historical generic risk depended on the full emtricitabine, tenofovir, formulation, and fixed-dose-combination patent portfolios.
Emtricitabine is a small molecule, so biosimilar analysis is not applicable.
Current freedom-to-operate analysis must focus on surviving patents covering specific combinations, formulations, processes, and tenofovir alafenamide products.

FAQs About U.S. Patent 6,642,245

Does Patent 6,642,245 cover Emtriva?

Historically, yes. Its core L-enantiomer method claims covered treatment of HIV infection using emtricitabine or a physiologically acceptable salt. The patent expired in 2021.

Does the patent cover Truvada?

It could have covered the emtricitabine component when Truvada was used to treat HIV infection, but Truvada also depended on separate tenofovir, combination, formulation, and method-of-use patents. The patent did not by itself define the entire Truvada patent estate.

Does Patent 6,642,245 cover HIV pre-exposure prophylaxis?

Not automatically. The claims recite treating HIV infection. PrEP is a prevention indication, and coverage would depend on claim construction, the approved indication, prescribing conduct, and other patent claims.

What does the 95% enantiomeric-purity limitation mean?

It narrows dependent claims to an administered form containing at least 95% of one enantiomer relative to the corresponding opposite enantiomer. It does not necessarily impose that threshold on every independent claim.

Can a generic company rely on the patent after its expiration?

No. An expired patent cannot support a new U.S. infringement injunction. A generic applicant must still address any other unexpired patents and FDA requirements applicable to the product.

References

United States Patent and Trademark Office. (2003). U.S. Patent No. 6,642,245: Methods of treating HIV infection.
United States Patent and Trademark Office. (n.d.). Patent term adjustment and patent term information.
U.S. Food and Drug Administration. (2003). Emtriva (emtricitabine) prescribing information.
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
Gilead Sciences, Inc. (n.d.). Annual reports and product information for emtricitabine-containing antiretroviral products.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	0513200	⤷ Start Trial	91073	Luxembourg	⤷ Start Trial
European Patent Office	0513200	⤷ Start Trial	300148	Netherlands	⤷ Start Trial
European Patent Office	0513200	⤷ Start Trial	SPC/GB04/016	United Kingdom	⤷ Start Trial
European Patent Office	0513200	⤷ Start Trial	SZ 7/2004	Austria	⤷ Start Trial
European Patent Office	0513200	⤷ Start Trial	C00513200/01	Switzerland	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 6,642,245

Summary for Patent: 6,642,245